As a result, the CAR exhibits strong in vivoin-vivo and in vitro tumor-killing capacity against EGFR-vIII mutant or EGFR-overexpressing tumor cells, but maintains low toxicity to EGFR normally expressed cells (43). This evidence concerns the gene EGFR and neoplasm.